Latest Breaking News On - Society of experimental biology - Page 5 : comparemela.com
COVID-19: Transmission and Therapeutics
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Metabolomic Profiling of Chronic Obstructive Pulmonary Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Advances in the Genetic Etiology of Hearing Impairment
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
A New microRNA Target for Treating Spinal Cord Injuries
News provided by
Share this article
WASHINGTON, June 9, 2021 /PRNewswire/ An article published in
Experimental Biology and Medicine (Volume 246, Issue 11, June 2021) describes a new target for treating spinal cord injuries. The study, led by Dr. Chunfang Wang, in the Shanxi Key Laboratory of Animal and Animal Model of Human Diseases at Shanxi Medical University in Taiyuan (China), reports that modulating the expression of a specific microRNA improves motor function in a mouse model of spinal cord injury.
Damage to the spinal cord results in changes in strength, sensation and other body functions below the site of the injury. Restoring motor function is a key factor in managing spinal cord injury. Injection of neural stems has been shown to be effective, but the availability of neural cells is limited by ethical and practical issues. Another option is stimulating the proliferation of undifferentiated neural stem cel
Share this article
WASHINGTON, March 16, 2021 /PRNewswire/ An article published in
Experimental Biology and Medicine (Volume 246, Issue 6, March, 2021) reports a new nucleic acid-based approach for therapeutics targeting inflammation. The study, led by Dr. Anthony Bell Jr, in the Department of Chemistry and Biochemistry at the University of San Diego in San Diego, CA (USA), reports four novel cruciform DNA ligands that exhibit increased nuclease-resistance, thermostability, and target-binding affinity.
HMGB1 (High Mobility Group B1) is an important molecular target in multiple human diseases including infectious diseases, ischemia, immune disorders, neurodegenerative diseases, metabolic disorders, and cancer. HMGB1 plays two different but critical roles inside and outside of cells. Inside cells, HMGB1 bends DNA into arrangements or scaffolds that facilitate gene expression. Outside cells, HMGB1 functions as a proinflammatory cytokine that can be either a friend or foe